Cover Image
市場調查報告書

惡性黑色素瘤治療的價格與償付

Malignant Melanoma Pricing and Reimbursement

出版商 Datamonitor Healthcare 商品編碼 342059
出版日期 內容資訊 英文 55 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
惡性黑色素瘤治療的價格與償付 Malignant Melanoma Pricing and Reimbursement
出版日期: 2015年09月30日 內容資訊: 英文 55 Pages
簡介

新的高額的黑色素瘤治療藥已可利用,患者可利用的藥品相關的付款者決策,到目前為止對以上變得重要起來。

本報告以付款者的採訪為基礎,提供到目前為止的付款者決策,未來預測的相關驗證等系統性資訊。

摘要整理

市場背景

  • 進入市場的新藥戲劇性地增加
  • 美國、日本、5大歐盟市場的上市產品
  • 治療的開發平台:後期階段
  • 價格的前提條件
  • 參考文獻
  • 美國
  • 價格
  • 償付
  • 參考文獻

日本

  • 成功的價格設定
  • Nivolumab
  • 參考文獻

5大歐盟市場

  • 價格
  • 償付與健康技術評估
  • 參考文獻

圖表

目錄
Product Code: DMKC0131939

Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs. Currently, the treatment of melanoma has a limited budgetary impact and Datamonitor Healthcare does not anticipate any immediate impact on the pricing of melanoma therapies. However, in the future, manufacturers may have to consider novel pricing arrangements for high-cost combination treatments.

This report addresses the following questions:

  • What are the main utilization management tools used by US payers for melanoma drugs and how will their use evolve in the future?
  • How concerned are the US payers regarding the growing budget impact of melanoma therapies?
  • Which melanoma drugs were the most successful in European health technology assessments and why?
  • In which countries are melanoma drugs reimbursed under risk-sharing agreements?
  • What levers are most commonly used by EU payers to limit the budget impact of melanoma therapies?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

MARKET CONTEXT

  • 1. Market entry of new drugs will dramatically increase the budget impact of melanoma Treatments
  • 2. Marketed malignant melanoma products in the US, Japan, and five major EU markets
  • 3. Pipeline malignant melanoma treatments in late-stage development
  • 4. Price assumptions
  • 5. Bibliography

US

  • 6. Pricing
  • 7. Reimbursement
  • 8. Bibliography

JAPAN

  • 9. Successful pricing outcomes hinge on receipt of a pricing premium
  • 10. Nivolumab was awarded a 60% innovation margin
  • 11. Bibliography

FIVE MAJOR EU MARKETS

  • 12. Pricing
  • 13. Reimbursement and health technology assessment
  • 14. Bibliography
Back to Top